• Policy
• Samsung Bioepis receives approval for its Soliris biosimilar
• by Lee, Hye-Kyung Jan 23, 2024 06:02am

• Policy
• Korean patients pay ₩10.5M for ₩300M Luxturna
• by Lee, Tak-Sun Jan 23, 2024 06:02am

• Policy
• Luxturna, Kerendia, & Raspirin will get new reimb standards
• by Lee, Jeong-Hwan Jan 22, 2024 05:49am

• Policy
• Forxiga withdraws from the Korean mkt despite reimbursement
• by Lee, Tak-Sun Jan 22, 2024 05:48am

• Policy
• P3T for chin fat reduction injection ‘AYP-101’ approved
• by Lee, Hye-Kyung Jan 19, 2024 05:45am

• Policy
• Emerging candidate for Dir. of the Pharmaceutical Benefits
• by Lee, Jeong-Hwan Jan 19, 2024 05:45am

• Policy
• Celltrion rebrands and sells self-manufactured drugs
• by Lee, Hye-Kyung Jan 19, 2024 05:44am

• Policy
• Moderna will only supply Spikevax Duo 2 in Korea
• by Lee, Hye-Kyung Jan 18, 2024 06:07am

• Policy
• Drug price cuts will be applied in bulk next month
• by Lee, Tak-Sun Jan 18, 2024 06:07am

• Policy
• Stability data requirement eased for metformin approvals
• by Lee, Hye-Kyung Jan 17, 2024 05:29am